Arcutis Biotherapeutics, Inc. ARQT
Set alert
31.26 USD -0.81 -2.53%
At close
31.00 -0.26 -0.83%
Pre-market · Nov 3, 7:32 AM ET
31.20 Day range 32.24
19.30 52-week range 33.30
- YTD
- +7.64%
- 1 year
- +23.51%
- Open
- 32.07
- Prev close
- 32.07
- Mkt cap
- 3.93B
- Vol
- 1.51M
- Avg vol
- 2.51M
- EPS
- 0.22
- P/E
- 142.09
- Div yield
- 0.00%
More statistics
- Low
- 31.20
- High
- 32.24
- Forward P/E
- 23.34
- Beta
- 1.63
- Short ratio
- 6.13
- Inst. own
- 108.57%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 4, 2026
- 50-d avg
- 26.66
- 200-d avg
- 25.25
- 1y target
- 39.13
1Y chart
Events in this range
- Feb 25, 2026Earnings: 0.13; estimate 0.03; surprise 333.33%
- May 6, 2026Earnings: -0.09; estimate -0.02; surprise -350%
- May 7, 2026Rating: Needham · Buy → Buy
- Aug 5, 2026Earnings: 0.11; estimate 0.05508; surprise 99.71%
- Aug 6, 2026Rating: Needham · Buy → Buy
- Aug 6, 2026Rating: Guggenheim · Buy → Buy
- Aug 6, 2026Rating: Morgan Stanley · Overweight → Overweight
- Oct 15, 2026Rating: Cantor Fitzgerald · — → Overweight
- Oct 19, 2026Rating: Guggenheim · Buy → Buy
Signals (56)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 22, 2026 | 1 week ago |
| RSI: Overbought | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 13, 2026 | 2 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 9, 2026 | 3 weeks ago |
| SMA: Bearish | Oct 2, 2026 | 1 month ago |
| MACD: Sell Signal | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| SMA: Bullish | Sep 21, 2026 | 1 month ago |
| SMA: Bearish | Sep 18, 2026 | 1 month ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| SMA: Bullish | Sep 16, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 14, 2026 | 1 month ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bearish | Aug 19, 2026 | 2 months ago |
| SMA: Bullish | Aug 18, 2026 | 2 months ago |
| SMA: Bearish | Aug 13, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 10, 2026 | 2 months ago |
| SMA: Bearish | Aug 7, 2026 | 2 months ago |
Newest 20 of 56.
Key statistics
- Market cap
- 3.93B
- Enterprise value
- 3.91B
- Trailing P/E
- 142.00
- Forward P/E
- 23.34
- PEG ratio
- 0.00
- Price / sales
- 8.46
- Price / book
- 17.79
- EPS (TTM)
- 0.22
- Beta
- 1.63
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 6.15%
- Revenue (TTM)
- 463.98M
- Revenue growth
- 59.30%
- Free cash flow
- 21.69M
- Total cash
- 238.55M
- Total debt
- 114.14M
- Return on equity
- 15.86%
- Shares outstanding
- 125.69M
- Short % of float
- 17.38%
- 50-day average
- 26.66
- 200-day average
- 25.25
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 39.13 +25.2% upside
Now 31.26
- Target (low)
- 34.00
- Target (mean)
- 39.13
- Target (high)
- 48.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy2
- Buy5
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.16833.
Financials — quick view
ARQT Revenue — quarterly 129.86M
ARQT Net income — quarterly 15.01M
ARQT EPS — quarterly 0.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.18 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.05508 | 0.11 | +0.05 | +99.71% |
| May 6, 2026 | Mar 31, 2026 | -0.02 | -0.09 | -0.07 | -350.00% |
| Feb 25, 2026 | Dec 31, 2025 | 0.03 | 0.13 | +0.10 | +333.33% |
| Oct 28, 2025 | Sep 30, 2025 | -0.10 | 0.06 | +0.16 | +160.00% |
| Aug 6, 2025 | Jun 30, 2025 | -0.18 | -0.13 | +0.05 | +27.78% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 19, 2026 | Guggenheim | main | Buy | Buy |
| Oct 15, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Aug 6, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Aug 6, 2026 | Guggenheim | main | Buy | Buy |
| Aug 6, 2026 | Needham | main | Buy | Buy |
| May 7, 2026 | Needham | reit | Buy | Buy |
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- arcutis.com
News
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth
- Arcutis Appoints Rob Scott, MD to Board of Directors
- Arcutis Management to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
- Guggenheim Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $44
- Why Is Arcutis Biotherapeutics Stock Surging Thursday?
- Cantor Fitzgerald Initiates Coverage On Arcutis Biotherapeutics with Overweight Rating, Announces Price Target of $48
- Arcutis Presents ZORYVE Data At EADV Congress
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- Arcutis Biotherapeutics’ Subsidiary Arcutis Canada Secures Health Canada Approval For Roflumilast Cream In Pediatric Atopic Dermatitis Patients
- Morgan Stanley Maintains Overweight on Arcutis Biotherapeutics, Raises Price Target to $38
Your note
Sign in to keep a note on ARQT — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BURNETT PATRICK | Officer | Sale | Aug 18, 2026 | 117,592 |
| CHAUDHURI BHASKAR | Director | Stock Award(Grant) | Jun 11, 2025 | 917,807 |
| EDWARDS LARRY TODD | Officer | Sale | Mar 1, 2026 | 175,178 |
| HERON PATRICK J | Director | Stock Award(Grant) | Jun 4, 2026 | 8,868,640 |
| MATSUDA MASARU | Officer | Sale | Sep 7, 2026 | 116,182 |
| PEETZ CHRISTOPHER | Director | Stock Award(Grant) | Jul 14, 2026 | 191,815 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Montanova Capital LLC | 9.89% | 12,437,000 | 388.53M | Jun 29, 2026 |
| Blackrock Inc. | 8.39% | 10,545,466 | 329.44M | Jun 29, 2026 |
| Frazier Life Sciences Management, L.P. | 7.86% | 9,874,511 | 308.48M | Jun 29, 2026 |
| Rubric Capital Management LP | 6.58% | 8,271,577 | 258.40M | Jun 29, 2026 |
| Polar Capital Holdings PLC | 5.26% | 6,606,945 | 206.40M | Jun 29, 2026 |
| State Street Corporation | 4.63% | 5,822,840 | 181.91M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.42% | 6,810,517 | 212.76M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.84% | 3,564,957 | 111.37M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.40% | 3,020,203 | 94.35M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.35% | 2,959,244 | 92.45M | Sep 29, 2026 |
| American Century Mutual Funds, Inc.-Small Cap Growth Fund | 1.17% | 1,466,411 | 45.81M | Jul 30, 2026 |
| Prudential Jennison Small Co Fd., Inc.-PGIM JENNISON SMALL COMPANY Fd. | 1.10% | 1,386,237 | 43.31M | Jun 29, 2026 |